PARP1 and neoplasm: Because PARP trapping mediates the anti-tumor activity of PARP inhibitors and acquired resistance [124, 125], novel PARP inhibitors that are not substrates for the former drug efflux with increased PARP trapping capacity, such as the recently developed veliparib derivative, are promising clinical candidates, especially for patients who have undergone chemotherapy [126, 127].